One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. 1985

P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet

The therapeutic benefits and toxicity profile of auranofin (AF) have been compared with that of gold sodium thiomalate (GSTM) over a one-year period in 120 patients with rheumatoid arthritis. A similar number of patients on both drugs remained in the study at one year (approximately 60%), and showed similar statistically significant improvement (p less than 0.01) in all clinical variables measured. At no time during the study was there a statistically significant difference in the clinical benefit obtained with either drug. Withdrawal from the study through lack of therapeutic benefit was twice as frequent with AF as with GSTM (11 compared to 6). Withdrawal due to a toxic reaction was twice as frequent and were potentially more serious with GSTM than with AF (15 compared to 9). We conclude that AF has a therapeutic potential similar to that of GSTM, however side effects were less prevalent and, when they did cause withdrawal of the drug, were potentially less serious.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001799 Blood Sedimentation Measurement of rate of settling of ERYTHROCYTES in blood. Erythrocyte Sedimentation,Erythrocyte Sedimentation Rate,Erythrocyte Sedimentation Rates,Rate, Erythrocyte Sedimentation,Rates, Erythrocyte Sedimentation,Sedimentation Rate, Erythrocyte,Sedimentation Rates, Erythrocyte,Sedimentation, Blood,Sedimentation, Erythrocyte
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D005260 Female Females
D006046 Gold A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.
D006051 Aurothioglucose A thioglucose derivative used as an antirheumatic and experimentally to produce obesity in animals. Gold Thioglucose,Aureotan,Auromyose,Aurothioglucose, Sodium Salt, beta-D Isomer,Aurothioglucose, beta-D Isomer,Gold-50,Solganal,Solganal B Oleosum,Solganol,Thioglucosoaurate,Aurothioglucose, beta D Isomer,B Oleosum, Solganal,Gold 50,Gold50,Oleosum, Solganal B,Thioglucose, Gold,beta-D Isomer Aurothioglucose
D006052 Gold Sodium Thiomalate A variable mixture of the mono- and disodium salts of gold thiomalic acid used mainly for its anti-inflammatory action in the treatment of rheumatoid arthritis. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. Aurothiomalate,Gold Thiomalate,Sodium Gold Thiomalate,Aurolate,Gold Disodium Thiomalate, Monohydrate,Gold Thiomalic Acid,Mercaptobutanedioic Acid Monogold(1+) Sodium Salt,Miocrin,Miocrisin,Monogold (1+) Disodium Thiomalate,Myochrysine,Myocrisin,Myocrysine,Sodium Aurothiomalate,Sodium Thiomalatoaurate,Tauredon,Aurothiomalate, Sodium,Gold Thiomalate, Sodium,Sodium Thiomalate, Gold,Thiomalate, Gold,Thiomalatoaurate, Sodium
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
February 1988, Klinische Wochenschrift,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
December 1990, Clinical rheumatology,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
February 1990, Ryumachi. [Rheumatism],
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
September 1987, Clinical rheumatology,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
January 1982, The Journal of rheumatology. Supplement,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
June 1994, Clinical rheumatology,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
January 1982, The Journal of rheumatology. Supplement,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
December 1983, The American journal of medicine,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
March 1984, Clinical rheumatology,
P Davis, and H Menard, and J Thompson, and M Harth, and F Beaudet
March 1984, Clinical rheumatology,
Copied contents to your clipboard!